Multiple endocrine neoplasia type 2 prevention: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
Line 7: | Line 7: | ||
! style="padding: 0 5px; font-size: 120%; background: #4479BA" align=left| ''{{fontcolor|#FFF| Surveillance of multiple endocrine neoplasia type 2}}'' | ! style="padding: 0 5px; font-size: 120%; background: #4479BA" align=left| ''{{fontcolor|#FFF| Surveillance of multiple endocrine neoplasia type 2}}'' | ||
|- | |- | ||
! style="padding: 0 5px; font-size: 95%; background: #DCDCDC" align=left| '''Serum | ! style="padding: 0 5px; font-size: 95%; background: #DCDCDC" align=left| '''Serum [[calcium]] level annually for people diagnosed with multiple endocrine neoplasia type 2A )''' | ||
|- | |- | ||
! style="padding: 0 5px; font-size: 95%; background: #DCDCDC" align=left | '''Recurrent or residual medullary thyroid cancer post | ! style="padding: 0 5px; font-size: 95%; background: #DCDCDC" align=left | '''Recurrent or residual [[medullary thyroid cancer]] post [[thyroidectomy]] is detected by measurement of serum [[calcitonin]] annually''' | ||
|- | |- | ||
! style="padding: 0 5px; font-size: 95%; background: #DCDCDC" align=left | ''' | ! style="padding: 0 5px; font-size: 95%; background: #DCDCDC" align=left | '''Catacholamines, [[epinephrine]] and [[norepinephrine]] yearly for multiple endocrine neoplasia type 2A and multiple endocrine neoplasia type 2B patients to detect [[pheochromocytoma]]''' | ||
|- | |- | ||
! style="padding: 0 5px; font-size: 95%; background: #DCDCDC" align=left | '''[[Magnetic resonance imaging]] and [[computerized tomography]] for [[pheochromocytoma]] every 2-4 years''' | ! style="padding: 0 5px; font-size: 95%; background: #DCDCDC" align=left | '''[[Magnetic resonance imaging]] and [[computerized tomography]] for [[pheochromocytoma]] every 2-4 years''' | ||
|- | |- | ||
! style="padding: 0 5px; font-size: 95%; background: #DCDCDC" align=left | '''[[Parathyroid hormone]] level yearly for | ! style="padding: 0 5px; font-size: 95%; background: #DCDCDC" align=left | '''[[Parathyroid hormone]] level yearly for multiple endocrine neoplasia type 2A to detect [[hypoparathyroidism]]''' | ||
|} | |} | ||
<br><br><br><br><br><br> | <br><br><br><br><br><br> |
Revision as of 18:54, 28 September 2015
Multiple endocrine neoplasia type 2 Microchapters |
Differentiating Multiple endocrine neoplasia type 2 from other Diseases |
---|
Diagnosis |
Treatment |
Multiple endocrine neoplasia type 2 prevention On the Web |
American Roentgen Ray Society Images of Multiple endocrine neoplasia type 2 prevention |
Directions to Hospitals Treating Multiple endocrine neoplasia type 2 |
Risk calculators and risk factors for Multiple endocrine neoplasia type 2 prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ammu Susheela, M.D. [2]
Overview
Secondary Prevention
Surveillance of multiple endocrine neoplasia type 2 |
---|
Serum calcium level annually for people diagnosed with multiple endocrine neoplasia type 2A ) |
Recurrent or residual medullary thyroid cancer post thyroidectomy is detected by measurement of serum calcitonin annually |
Catacholamines, epinephrine and norepinephrine yearly for multiple endocrine neoplasia type 2A and multiple endocrine neoplasia type 2B patients to detect pheochromocytoma |
Magnetic resonance imaging and computerized tomography for pheochromocytoma every 2-4 years |
Parathyroid hormone level yearly for multiple endocrine neoplasia type 2A to detect hypoparathyroidism |